Modulating the tumor microenvironment through chemokine disruption

Immuno-Oncology Insights 2023; 4(6), 243–248


Published: 24 August 2023
Avital Barak

Roisin McGuigan, Commissioning Editor, Immuno-Oncology Insights, speaks to
Avital Barak, VP of Clinical Development and Medical Affairs, TME Pharma, about chemokine inhibition as an approach to modulating the TME, current tools and approaches to tackling the tumor microenvironment, and the explosion of innovation in this space.